Mebendazole is an old parasitic drug for whipworm, pinworm, round worm, and hookworm. It has been used for decades with no known clinical toxicity. It was first synthesized in 1968 and FDA approved in 1972. It is an inexpensive generic drug available in United States.
There is considerable interest in this drug as a re-purposed anticancer drug because it serves as a microtubule inhibitor. It is like the taxane class of chemotherapy drugs such as paclitaxel, and docetaxel. It also shares similarity with other microtubule destabilizing drugs such as vinblastine, vincristine, and colchicine. As a cancer treatment mebendazole is useful because microtubules are components of the spindle structures used in cell division, mitosis, and other important cell functions of the cancer cell.
In 2019 Dr. Andrea Guerrini reviewed all the medical literature of mebendazole and its desirable characteristics. The cancer characteristics were as follows: It inhibits tubulin polymerization, inhibits tumor angiogenesis, inhibits matrix metallic proteins, inhibits multidrug resistance.
Therefore, it has synergy with radiation and chemotherapy and decrease metastatic spread and improves survival.
It has been studied in various types of cancers including colon, ovarian cancer, multiple myeloma, melanoma, lung cancer, breast cancer, brain cancer, squamous cell carcinoma, gastric cancer, leukemia, and malignant ascites.
If you would like more information on mebendazole, re-purposed cancer drugs, low-dose metronomic genomic chemotherapy, natural substances for cancer, cancer vaccines we can help.
Please call us at 480-361-7020